# Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease

> **NCT04352803** · PHASE1 · UNKNOWN · sponsor: **Regeneris Medical** · enrollment: 20 (estimated)

## Conditions studied

- Covid-19 Pneumonia
- Cyotokine Storm

## Interventions

- **BIOLOGICAL:** Autologous Adipose MSC's

## Key facts

- **NCT ID:** NCT04352803
- **Lead sponsor:** Regeneris Medical
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04
- **Primary completion:** 2024-04
- **Final completion:** 2026-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352803, "Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04352803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*